SubsidieMeestersNext-generation heart bypass grafts to naturally restore cardiovascular function.
Xeltis aims to clinically validate a restorative vascular graft (XABG) to treat coronary artery disease without vein harvesting, enhancing patient outcomes and reducing healthcare costs.
Projectdetails
Introduction
Coronary Artery Disease is caused by narrowing of heart arteries that supply blood, often due to atherosclerosis.
Treatment Options
Coronary artery bypass grafting (CABG) is the gold standard surgery to treat it, and it commonly involves harvesting patients' veins from the legs as grafts.
Impact on Patients
This collection affects patients causing chronic pain and costly complications. It also has a high failure rate with over 20% of implants occluded after 1 year.
Innovative Solution
Xeltis has developed a unique restorative vascular graft (XABG) that eliminates the need for vein harvesting.
Advantages of XABG
The implant provides a homing structure for cells in which cardiac and vascular tissues can be naturally restored, with the related advantages and benefits for patients and the healthcare system.
Progress and Future Plans
We have proven our technology in first niche applications, as well as completed pre-clinical studies successfully for XABG.
Next Steps
Now, we plan to perform a full clinical validation to obtain a CE mark in Europe and start market deployment and commercial up-scaling.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.481.701 |
| Totale projectbegroting | € 4.205.283 |
Tijdlijn
| Startdatum | 1-12-2022 |
| Einddatum | 30-11-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- XELTIS BVpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Minimally invasive suturing for vascular bore closure and heart defect repairNovelrad's NVCD closure device aims to minimize complications in large-bore vascular closures during cardiac surgeries through innovative micro-suturing technology, facilitating safer and faster procedures. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Revolutionary vascular repair patch to treat aortic dissectionsAortyx's biomimetic bioresorbable adhesive patch aims to treat aortic dissections via endovascular deployment, enhancing natural repair and reducing mortality compared to traditional stents. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Bypassing open heart surgery with Excimer Laser Assisted Non Occlusive Anastomosis (ELANA®)AMT Medical aims to revolutionize coronary artery disease treatment by developing a minimally invasive, cost-effective CABG surgery using innovative ELANA technology, seeking $7.5M for clinical validation and market entry. | EIC Accelerator | € 2.497.469 | 2022 | Details |
A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patientsreBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients. | EIC Accelerator | € 2.499.999 | 2023 | Details |
THE NEXT STENT GENERATION: A FIRST-IN-CLASS REGENERATIVE NANOFIBER STENT TO RECONSTRUCT ARTERIES FROM THE INSIDE OUTSTENTiT aims to revolutionize BTK-CLI treatment with a regenerative stent that promotes vascular restoration and reduces complications, seeking €2.5M in grants and €10M in equity for clinical studies. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Minimally invasive suturing for vascular bore closure and heart defect repair
Novelrad's NVCD closure device aims to minimize complications in large-bore vascular closures during cardiac surgeries through innovative micro-suturing technology, facilitating safer and faster procedures.
Revolutionary vascular repair patch to treat aortic dissections
Aortyx's biomimetic bioresorbable adhesive patch aims to treat aortic dissections via endovascular deployment, enhancing natural repair and reducing mortality compared to traditional stents.
Bypassing open heart surgery with Excimer Laser Assisted Non Occlusive Anastomosis (ELANA®)
AMT Medical aims to revolutionize coronary artery disease treatment by developing a minimally invasive, cost-effective CABG surgery using innovative ELANA technology, seeking $7.5M for clinical validation and market entry.
A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patients
reBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients.
THE NEXT STENT GENERATION: A FIRST-IN-CLASS REGENERATIVE NANOFIBER STENT TO RECONSTRUCT ARTERIES FROM THE INSIDE OUT
STENTiT aims to revolutionize BTK-CLI treatment with a regenerative stent that promotes vascular restoration and reduces complications, seeking €2.5M in grants and €10M in equity for clinical studies.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
BIOPASSHet BIOPASS-project ontwikkelt een minimaal-invasieve bypasstechniek met bio afbreekbare donorvaten om complicaties te verminderen en herstel te versnellen, met als doel een innovatieve oplossing voor hartpatiënten. | Mkb-innovati... | € 349.265 | 2017 | Details |
XELENA Heart BypassXeltis en AMT Medical ontwikkelen een innovatieve bypass-technologie met regeneratieve kunstvaten en hechtingloze bevestiging, gericht op veiligere operaties en verbeterde patiëntresultaten. | Mkb-innovati... | € 318.850 | 2020 | Details |
Blood as energy source to power smart cardiac devicesThe BLOOD2POWER project aims to develop energy-harvesting vascular grafts using triboelectric nanogenerators to monitor performance and prevent failure through wireless data transmission. | EIC Pathfinder | € 2.885.525 | 2023 | Details |
MicroHeartHet project ontwikkelt een gestandaardiseerd productieproces voor de ELANA Heart Bypass, een minimaal-invasieve behandeling voor coronaire hartziekten, ter verbetering van patiëntenzorg en commercialisatie. | Mkb-innovati... | € 155.525 | 2018 | Details |
biomimetic engineered chordae tendineae for valve repair and regenerationThis project aims to develop and validate BioChord, a bioengineered regenerative chordae tendineae for mitral valve repair, enhancing durability and promoting tissue restoration. | ERC Proof of... | € 150.000 | 2023 | Details |
BIOPASS
Het BIOPASS-project ontwikkelt een minimaal-invasieve bypasstechniek met bio afbreekbare donorvaten om complicaties te verminderen en herstel te versnellen, met als doel een innovatieve oplossing voor hartpatiënten.
XELENA Heart Bypass
Xeltis en AMT Medical ontwikkelen een innovatieve bypass-technologie met regeneratieve kunstvaten en hechtingloze bevestiging, gericht op veiligere operaties en verbeterde patiëntresultaten.
Blood as energy source to power smart cardiac devices
The BLOOD2POWER project aims to develop energy-harvesting vascular grafts using triboelectric nanogenerators to monitor performance and prevent failure through wireless data transmission.
MicroHeart
Het project ontwikkelt een gestandaardiseerd productieproces voor de ELANA Heart Bypass, een minimaal-invasieve behandeling voor coronaire hartziekten, ter verbetering van patiëntenzorg en commercialisatie.
biomimetic engineered chordae tendineae for valve repair and regeneration
This project aims to develop and validate BioChord, a bioengineered regenerative chordae tendineae for mitral valve repair, enhancing durability and promoting tissue restoration.